Quest PharmaTech Inc
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Quest PharmaTech Inc (QPTFF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of October 2025: -0.001x
Based on the latest financial reports, Quest PharmaTech Inc (QPTFF) has a cash flow conversion efficiency ratio of -0.001x as of October 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.00K) by net assets ($23.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Quest PharmaTech Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Quest PharmaTech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Quest PharmaTech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quest PharmaTech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ck Infra Holdings Ltd
LSE:CKI
|
0.002x |
|
FP Newspapers Inc
PINK:FPNUF
|
0.095x |
|
Ensign Group Inc
STU:EGB
|
0.046x |
|
Feishang Anthracite Resources Limited
PINK:FSHRF
|
-0.006x |
|
Metrospaces Inc
PINK:MSPC
|
0.055x |
|
Ricky Putra Globalindo Tbk
JK:RICY
|
-0.004x |
|
Integrated Media Technology Ltd
NASDAQ:IMTE
|
0.341x |
|
EGDB11
SA:EGDB11
|
N/A |
Annual Cash Flow Conversion Efficiency for Quest PharmaTech Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Quest PharmaTech Inc from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | $21.40 Million | $-511.88K | -0.024x | -61.77% |
| 2024-01-31 | $23.15 Million | $-342.42K | -0.015x | +31.49% |
| 2023-01-31 | $25.70 Million | $-554.68K | -0.022x | -1042.76% |
| 2022-01-31 | $90.41 Million | $-170.78K | -0.002x | +86.84% |
| 2021-01-31 | $175.22 Million | $-2.52 Million | -0.014x | -101.80% |
| 2020-01-31 | $-7.99 Million | $-6.38 Million | 0.798x | -49.93% |
| 2019-01-31 | $-4.33 Million | $-6.91 Million | 1.594x | +161.66% |
| 2018-01-31 | $2.83 Million | $-7.33 Million | -2.584x | -496.23% |
| 2017-01-31 | $10.63 Million | $-4.61 Million | -0.433x | -141.22% |
| 2016-01-31 | $-2.43 Million | $-2.56 Million | 1.052x | +102.15% |
| 2015-01-31 | $-3.73 Million | $-1.94 Million | 0.520x | -35.94% |
| 2014-01-31 | $-2.41 Million | $-1.96 Million | 0.812x | -- |